Who is sponsoring NCT03464513?

NCT03464513 is sponsored by Assiut University.

What drugs are being tested in NCT03464513?

Interventions in NCT03464513: Multislice CT Angiography.

What condition does NCT03464513 study?

NCT03464513 studies Lower Gastrointestinal Bleeding.

Is NCT03464513 still recruiting?

NCT03464513 is currently status unknown. Last updated 14 March 2018.

Last reviewed 2018-03-14 · How we verify

NCT03464513

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

MSCT Angiography in Bleeding

Status unknown NA Last updated 14 March 2018

What this trial tests

NA trial testing Multislice CT Angiography in Lower Gastrointestinal Bleeding in 25 participants. Status unknown.

Timeline

1 April 2018

Primary endpoint
1 April 2019

1 April 2020

Quick facts

Lead sponsor	Assiut University
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	25
Start date	1 April 2018
Primary completion	1 April 2019
Estimated completion	1 April 2020

Drugs / interventions tested

Multislice CT Angiography

Conditions studied

Lower Gastrointestinal Bleeding — all drugs for Lower Gastrointestinal Bleeding →

Sponsor

Assiut University

Who can join

Eligibility, any sex, with Lower Gastrointestinal Bleeding. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Lower gastrointestinal bleeding occurs distal to the ligament of treitz and may involve the small bowel, colon and rectum . Active lower gastrointestinal bleeding is a common, potentially life threatening medical presentation that can be challenging to localize and treat . There are many diseases that may cause lower gastrointestinal bleeding, including angiodysplasia, diverticulosis, benign or malignant bowel neoplasm, inflammatory bowel disease, ischemic bowel disease, and infectious bowel disease. Often, gastrointestinal bleeding will stop spontaneously, but in approximately 25% of patients, bleeding is massive or recurrent, requiring imaging localization and directed therapy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Assiut University trials

Trials by the same sponsor.

NCT07423312 — Lead Exposure and Multiple Sclerosis · not yet recruiting
NCT07234526 — Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients · not yet recruiting
NCT07273214 — Knowledge, Attitude and Practice of Third Trimester Pregnant Mothers Towards Self-Medication in Assiut, Egypt · not yet recruiting
NCT07194863 — Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD · not yet recruiting
NCT07053709 — Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03464513 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assiut University
Last refreshed: 14 March 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03464513.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing